Viridian Therapeutics Long Term Debt

As of the most recent data (June 2026), VRDN shows a long-term debt of $240M. That compares with $12M in the prior-year period — up 1860.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, VRDN's long-term debt is now $240M (was $12M) — a 1860.3% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Viridian Therapeutics is outperforming or lagging.

Tracking VRDN's long-term debt over time shows whether Viridian Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $240M That compares with $12M in the prior-year period — up 1860.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Viridian Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $240M) with ownership activity and broader fundamentals.

Viridian Therapeutics's long-term debt is $240M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.